Article

Risk Characterization of Botanical Extracts Containing Hydroxyanthracenes as Determined by a Validated Micronucleus In Vitro Assay

Gloria Melzi [ID], Corrado L. Galli * and Marina Marinovich [ID]

Department of Pharmacological and Biomolecular Sciences (DiSFeB)—"Rodolfo Paoletti", Università degli Studi di Milano, 20133 Milan, Italy; gloria.melzi@unimi.it (G.M.); marina.marinovich@unimi.it (M.M.)
* Correspondence: corrado.galli@unimi.it

Abstract: Extracts of *Rheum palmatum* L., *Rhamnus purshiana* DC., *Rhamnus frangula* L., and *Cassia senna* L. are used in traditional medicine thanks to their beneficial properties. These species contain hydroxyanthracene derivatives, considered genotoxic and possibly related to colorectal cancer development. This research aimed to study, using a micronucleus assay in vitro, the genotoxic potential of *Rheum palmatum* L., *Rhamnus purshiana* DC., *Rhamnus frangula* L. (bark), and *Cassia senna* L. (leaves and fruits) extracts. The extracts were evaluated at different concentrations: from 0 to 2000 μg/mL for *Rhamnus purshiana* DC, from 0 to 2500 μg/mL for *Rheum palmatum* L. and *Rhamnus frangula* L., and from 0 to 5000 μg/mL for *Cassia senna* L. The cytokinesis-block proliferation index was calculated to analyse if the used concentrations showed cytotoxicity. The hydroxyanthracene content varied between 0.06% and 0.23% for aloe-emodin, and between 0.07% and 0.16% for emodin and rhein. No cytotoxic effect was detected at any of these concentrations. Micronucleus analyses showed a lack of genotoxicity for all the extracts tested. These results show that *Rheum palmatum* L., *Rhamnus purshiana* DC, *Rhamnus frangula* L., and *Cassia senna* L. extracts do not induce genotoxicity since no increase in micronuclei formation in human lymphocytes in vitro was detected.

Keywords: hydroxyanthracenes; herbal preparations; genotoxicity; OCED 487 micronucleus assay in vitro; botanicals

1. Introduction

In recent years, numerous studies have focused on the safety and toxicity of many botanical products that have been used as medicines and food supplements for many years. Botanical species and extracts are used as active pharmaceutical ingredients in traditional Chinese medicine, and their use is spreading all over the world [1].

Plant extracts are complex mixtures with biological properties. Among the components of several extracts, there are hydroxyanthracenes and their derivatives. The safety of hydroxyanthracenes was evaluated by the Panel of the EFSA, Food Additives, and Nutrient Sources added to Food (EFSA-ANS Panel) in 2018, which concluded that "*hydroxyanthracene derivatives should be regarded as genotoxic and carcinogenic unless there are specific data to the contrary, [. . .] and that there is a safety concern for extracts containing hydroxyanthracene derivatives although uncertainty persists*" [2]. Many botanical preparations containing hydroxyanthracenes are under community scrutiny for new evaluations; such extracts include the ones obtained from the root or rhizome of *Rheum palmatum* L. and *Rheum officinale* Baillon, from the leaves and fruits of *Cassia senna* L., and from the bark of *Rhamnus frangula* L. and *Rhamnus purshiana* DC. [3].

According to the World Health Organization (WHO), the use of these types of products containing anthraquinones and hydroxyanthracenes should be limited to an average dose of 0.5–1.5 g of dried plant material or in decoction, a safe individual dose being 10–30 mg of hydroxyanthraquinones per day [4]. Moreover, they should not be used for more

than 1–2 weeks due to their laxative properties that could potentially induce electrolyte imbalances. The European Medicines Agency (EMA) has stated that 30 mg/day should be the maximum dosage of hydroxyanthracene contents in medicinal products to be used as a laxative for adults, elderly, and adolescents over 12 years [5].

In traditional medicine, *R. palmatum* L. (Chinese rhubarb) is used to treat constipation, gastrointestinal haemorrhage, and ulcers [6,7]. Small doses of rhubarb extract show good digestive properties, while at higher doses it acts as a laxative. It is also used for its antibacterial, antioxidant, and anti-inflammatory effects [8,9]. *C. senna* L. is added in several herbal teas and used for purging and in weight loss [10]. *R. frangula* L. and *R. purshiana* L. are also used as purgatives. Hydroxyanthracene derivatives are present in these extracts as emodin, aloe-emodin, chrysophanol, physcion, and rhein [11].

We have recently demonstrated the lack of genotoxic effects in colon and kidney cells after in vivo treatment with *Aloe ferox* extract, containing hydroxyanthracene derivatives, and pure aloe-emodin in a comet assay [12,13]. Moreover, we have proved the absence of a genotoxic effect of a *Rheum palmatum* L. rhizome extract in *Salmonella typhimurium*, TA1535, TA1537, TA98, TA100, and *Escherichia coli* (WP2 uvrA) strains with the Ames test; the same extract was tested for micronuclei formation in isolated human lymphocytes showing negative results [14].

In this research, we investigated the genotoxic potential of five different extracts (*R. palmatum* L., *R. purshiana* DC, *R. frangula* L., and *C. senna* L. from fruits and leaves).

2. Materials and Methods

2.1. Extract Preparation

Extracts from *R. palmatum* L. (PAL), *R. purshiana* DC (PUR), and *R. frangula* L. (FRA), *C. senna* L. (leaves and fruits, CSL and CSF) were prepared and characterized analytically according to good agricultural and collection practices (GACP) and good manufacturing practices (GMP). Extract preparation is described in detail in the Supplementary Materials.

The PAL, PUR, and FRA extracts were kept at room temperature and prepared for the experiment immediately before use, dissolved in dimethylsulphoxide (DMSO, AppliChem, Darmstadt, Germany). One of the extracts of *C. senna* L. (from fruits; CSF) was kept at room temperature and prepared for the experiment immediately before use, dissolved in water, while the other (from leaves; CSL) was prepared in a complete culture medium.

2.2. Extract Characterization

Samples were characterized according to the specific analytical methods described in the pharmacopeia. In addition, aloin (A and B), aloe-emodin, rhein, and emodin were identified and quantified using an HPLC-UV method. More information on the extracts is available in the Supplementary Materials. The analytical methods, including the HPLC-UV analyses, were performed according to the relevant monographs for the four extracts reported in the current European Pharmacopoeia.

2.3. Peripheral Blood Lymphocyte Cultures

Blood samples were collected from healthy, young (under 35 years old), male, non-smoker donors, with no known illnesses or recent exposure to genotoxic agents, upon informed consent. Establishment of the blood cultures was done within 30 h from blood collection, preparing a 13% mixture of whole blood in a medium. The culture medium was Dulbecco's Modified Eagles medium/Ham's F12 (mixture 1:1) with 200 mM GlutaMAX™. The medium was completed with penicillin/streptomycin (100 U/mL/100 μg/mL), mitogen phytohaemagglutinin (PHA, 3 μg/mL as solvent lyophilizate), 10% foetal bovine serum (FBS), 10 mM HEPES, and the anticoagulant heparin (125 U.S.P.-U/mL). Cells were incubated at 37 °C with 5.5% CO_2 in humidified air. For the analysis, only human lymphocytes were considered.

2.4. Mammalian Microsomal Fraction S9 Mix

The limited metabolic activation in in vitro systems is usually a major issue for the evaluation of genotoxic potential. For this reason, an exogenous metabolic activation was performed with the S9 mix obtained from rat liver. The S9 mix was prepared by ICCR-Roßdorf GmbH and stored following the currently valid version of the ICCR-Roßdorf standard operating procedure for rat liver S9 preparation.

The S9 supernatant was thawed and mixed with a cofactor solution and used at the final protein concentration of 0.75 mg/mL in the cultures. The S9 mix contains $MgCl_2$ (8 mM), KCl (33 mM), glucose-6-phosphate (5 mM), and NADP (4 mM) in a sodium ortho-phosphate buffer (100 mM, pH 7.4).

2.5. Concentration Selection, Treatments, and Micronucleus Assay Preparation

First, the concentrations for the in vitro micronucleus test were selected according to the Organisation for Economic Co-operation and Development (OECD) guidelines. Different concentrations were chosen for each extract, taking into consideration the solubility properties of each of them. The concentrations analysed for the cytotoxicity evaluation ranged from 16.2 to 2500 µg/mL for PAL and FRA, from 13.0 to 2000 µg/mL for PUR, from 32.5 to 5000 µg/mL for CSF, and from 18.9 to 5000 µg/mL for CSL. No precipitation at the end of the treatment was observed either in the absence or the presence of the S9 mix for CSF, while it was observed starting at 466 µg/mL for PAL, at 816 µg/mL for FRA, at 1143 µg/mL for PUR, and at 544 µg/mL and above in the absence of the S9 mix and at 952 µg/mL and above in the presence of the S9 mix for CSL. The selected concentrations (expressed in w/v) for the treatment are reported in Table 1.

Table 1. Doses selected for the treatments with the extracts of *Rheum palmatum* L. (PAL), *Rhamnus purshiana* DC (PUR), *Rhamnus frangula* L. (FRA), *Cassia senna* L. from fruits (CSF) and leaves (CSL). The concentrations selected for the treatments are reported in bold and are expressed in w/v.

Extract	Exposure	Concentrations in µg/mL									
PAL											
Without S9	3 h	16.2	28.4	49.7	**87.0**	**152**	**267**	466 [P]	816 [P]	1429 [P]	2500 [P]
	28 h	--	75.0	131	230	**402**	**482**	**579**	649	833	1000 [P]
With S9	3 h	16.2	28.4	49.7	**87.0**	**152**	**267**	**466** [P]	816 [P]	1429 [P]	2500 [P]
PUR											
Without S9	3 h	13.0	22.7	39.8	69.9	122	213	**373**	**653**	**1143** [P]	2000 [P]
	28 h	--	--	63.2	111	193	339	**593**	**889**	**1333** [P]	2000 [P]
With S9	3 h	13.0	22.7	39.8	69.6	122	213	**373**	**653**	**1143** [P]	2000 [P]
FRA											
Without S9	3 h	16.2	28.4	50.0	87.0	152	**267**	**466**	**816** [P]	1429 [P]	2500 [P]
	28 h	--	--	39.8	69.6	122	213	**373**	**653**	**1143** [P]	2000 [P]
With S9	3 h	16.2	28.4	50.0	87.0	**152**	267	**466**	**816** [P]	1429 [P]	2500 [P]
CSF											
Without S9	3 h	32.5	56.8	99.5	174	305	533	933	**1633**	**2857**	**5000**
	28 h	--	--	--	--	305	533	933	**1633**	**2857**	**5000**
With S9	3 h	32.5	56.8	99.5	174	305	533	933	**1633**	**2857**	**5000**
CSL											
Without S9	3 h	18.9	33.2	58.0	102	**178**	**311**	**544** [P]	952 [P]	1667 [P]	5000 [P]
	28 h	--	--	99.5	**174**	305	**533** [P]	933 [P]	1633 [P]	2857 [P]	5000 [P]
With S9	3 h	18.9	33.2	58.0	102	178	**311**	**544**	**952** [P]	1667 [P]	5000 [P]

[P] Presence of precipitation at the end of the treatment.

Human lymphocytes proliferation was stimulated by adding the mitogen PHA to the culture medium for 48 h. To check the possible mutagenic effect of the extracts, two different treatments were performed. Forty-eight hours after seeding, 10 mL of the blood cultures was set up in parallel in 25 cm^2 flasks for each extract concentration. For the treatment, the medium used was serum-free. For a set of samples, metabolic activation was promoted by the addition of the S9 mix (50 µL/mL culture medium). After 3 h, the cells were centrifuged for 5 min. The supernatant was removed, and the cells were resuspended and washed two times with saline G (pH 7.2, containing 8000 mg/L NaCl, 400 mg/L KCl, 1100 mg/L glucose × H_2O, 192 mg/L Na_2HPO_4 × 2 H_2O and 150 mg/L KH_2PO_4). The cells were resuspended in a culture medium with 10% FBS (*v/v*) in the presence of cytochalasin B (4–6 µg/mL) and cultured for 25 h [15].

Another set of cells were treated with the extracts and in the presence of cytochalasin B (4–6 µg/mL), and these cells were treated for 28 h [16].

For both treatments, the cultures were harvested by centrifugation 28 h after the beginning of each treatment. The cells were washed in saline G, resuspended in 5 mL KCl solution (0.0375 M), and incubated at 37 °C for 20 min. The cells were fixed with a 1 mL ice-cold mixture of methanol and glacial acetic acid (19 parts plus 1 part, respectively) and kept cold. The slides were prepared by dropping the cell suspension into fresh fixative. The cells were stained with Giemsa, mounted after drying, and covered with a coverslip.

2.6. Slide Evaluation and Cytotoxicity Analysis

The slides were evaluated with a 40× magnification. The micronuclei (MN) were counted in cells showing a clearly visible area of cytoplasm. MN were evaluated according to previously published criteria [17]. One thousand binucleated cells per culture were scored for cytogenetic damage on coded slides. The results are reported as % micronucleated cells. The cytotoxic effect was reported using the cytokinesis-block proliferation index (CBPI) (Formula (1) below) and cytotoxicity was expressed as % cytostasis (Formula (2)). A CBPI equal to 1 (all cells are mononucleated) means 100% cytostasis.

$$\text{CBPI} = \frac{\text{mononucleated cells} + 2 \times \text{binucleated cells} + 3 \times \text{multinucleated cells}}{\text{total number of cells counted}} \qquad (1)$$

$$\% \text{ cytostasis} = 100 - 100 \left(\frac{\text{CBPI extract} - 1}{\text{CBPI control} - 1} \right) \qquad (2)$$

The cytotoxicity of a product is characterized by the percentages of reduction in the CBPI in comparison to the controls (% cytostasis) by counting 500 cells per culture. The data related to cytostasis and CBPI for the concentrations not evaluated for MN formation are reported in the Supplementary Material.

2.7. Statistical Analysis

Statistical significance was confirmed by a chi-squared test ($p < 0.05$), using a validated test script in R. The statistical analysis was conducted to detect significant differences in MN presence in treated samples compared to the concurrent solvent control. A linear regression was performed using R. A trend is considered significant whenever the *p*-value is below 0.05.

3. Results

3.1. Characterization

The samples were characterized according to the specific analytical methods described in the pharmacopeia. Table 2a,b report the percentage of hydroxyanthracene derivatives in the different botanical extracts tested in this study, identified by means of a high-performance liquid chromatograph-ultraviolet (HPLC-UV) detector.

Table 2. (**a**) Composition of the extracts. All the data are expressed in percentages of the total weight of the extract. In addition, aloin (A and B), aloe-emodin, rhein, and emodin were identified and quantified using an HPLC-UV method. (**b**) Levels of aloin A and B, aloe emodin, rhein, and emodin in the tested extracts. All the data are expressed in percentages of the total weight of the extract.

(a)					
	PAL	**PUR**	**FRA**	**CSF**	**CSL**
Loss on drying	2.30	4.00	3.20	4.50	3.70
Hydroxyanthracene Glycosides	5.50	19.50	n.a.	n.a.	n.a.
Cascarosides	n.a.	78.70	n.a.	n.a.	n.a.
Glucofrangulins	n.a.	n.a.	16.85	n.a.	n.a.
Sennoside B [a]	n.a.	n.a.	n.a.	19.14	n.a.
Sennoside B [b]	n.a.	n.a.	n..a.	n.a.	8.90

(b)					
	PAL	**PUR**	**FRA**	**CSF**	**CSL**
Aloin A	n.d.	0.57	n.d.	Traces	Traces
Aloin B	n.d.	0.49	n.d.	0.032	0.016
Aloe-emodin	0.10	0.06	0.23	Traces	0.02
Rhein	0.20	0.00	n.d.	0.075	0.09
Emodin	0.10	0.16	0.07	Traces	Traces

n.a. = not applicable; n.d. = not detected; [a] pharmacopeia HPLC method; [b] pharmacopeia photometric method. PAL: *Rheum palmatum* L.; PUR: *Rhamnus purshiana* DC; FRA: *Rhamnus frangula* L.; CSF: *Cassia senna* L. from fruits; CSL: *Cassia senna* L. from leaves.

3.2. Cytokinesis-Block Proliferation Index and Cytostasis

The CBPI and cytostasis were calculated for each of the treatments to obtain data on the cytotoxicity of the extracts. The results are presented in Tables 3–7. The treatment with PAL (Table 3) in the absence of the S9 mix at the highest concentrations, starting from 466 µg/mL, induced moderate cytotoxicity, while in the presence of the S9 mix, no cytotoxicity was detected. Following the long treatment, cytotoxicity was highlighted at the highest concentrations (from 833 µg/mL). For the treatment with PUR (Table 4), no cytotoxicity was observed at any concentration, while following the long treatment, the highest concentrations that showed precipitation at the end of the treatment (1333 and 2000 µg/mL) resulted in moderate cytotoxicity. For the treatment with FRA (Table 5), no cytotoxicity was observed at any concentration in the absence of the S9 mix, while in the presence of S9, the highest concentrations (starting from 816 µg/mL) induced moderate cytotoxicity. The treatment with CSF (Table 6) and CSL (Table 7) did not show cytotoxicity at any of the evaluated concentrations. All experimental plant specimens' pictures are shown in Figures 1–5.

Table 3. Evaluation of the cytokinesis-block proliferation index (CBPI), cytostasis, and micronuclei in human lymphocytes after short treatment in the absence or presence of the S9 fraction (3 h) or long treatment in the absence of S9 fraction (28 h) with the extract of *Rheum palmatum* L. (PAL).

Exposure Time	S9 Mix	Concentration (µg/mL)	CBPI	Cytostasis in %	Micronucleated Cells in %
		DMSO [a]	1.68	-	0.95
		MMC 0.6	1.47	30.4	7.45 *
3 h	−	87.0	1.53	21.2	0.55
		152	1.51	24.7	0.45
		267	1.49	27.9	0.50
Trend test: *p*-value 0.220					

Table 3. *Cont.*

Exposure Time	S9 Mix	Concentration (µg/mL)	CBPI	Cytostasis in %	Micronucleated Cells in %
3 h	+	DMSO	1.65	-	0.68
		CPA 15.0	1.49	25.6	3.15 *
		152	1.62	4.7	0.63
		267	1.65	n.c.	0.85
		466 [P]	1.60	8.9	1.10 *
		Trend test: *p*-value 0.557			
28 h	−	DMSO	1.70	-	0.25
		VIN 12.5 [b]	1.59	16.1	3.10 *
		402	1.50	28.7	0.45
		482	1.41	42.5	0.65
		579	1.34	51.7	0.40
		Trend test: *p*-value 0.336			

[a] Concentration of 1.0% (*v/v*); [b] ng/mL; [P] precipitation at the end of the treatment; n.c.: not calculated, as the CBPI value is equal to or higher than the solvent control value; * statistically significant vs. solvent control (χ^2 test $p < 0.05$). DMSO: dimethylsulfoxide; MMC: mitomycin C; CPA: cyclophosphamide; VIN: vinblastine.

Figure 1. Plant of *Rheum palmatum* L. (PAL). The extract tested in the study was obtained from bark.

Table 4. Evaluation of the cytokinesis-block proliferation index (CBPI), cytostasis, and micronuclei in human lymphocytes after short treatment in the absence or presence of the S9 fraction (3 h) or long treatment in the absence of the S9 fraction (28 h) with the extract of *Rhamnus purshiana* DC (PUR).

Exposure Time	S9 Mix	Concentration (µg/mL)	CBPI	Cytostasis in %	Micronucleated Cells in %
3 h	−	DMSO [a]	1.65	-	0.40
		MMC 0.8	1.42	35.5	3.95 *
		373	1.58	12.1	0.45
		653	1.60	7.8	0.40
		1143 [P]	1.57	12.8	0.55
		Trend test: *p*-value 0.201			

Table 4. *Cont.*

Exposure Time	S9 Mix	Concentration (µg/mL)	CBPI	Cytostasis in %	Micronucleated Cells in %
3 h	+	DMSO	1.83	-	0.30
		CPA 10.0	1.46	44.5	1.75 *
		373	1.79	5.0	0.55
		653	1.53	36.3	0.40
		1143 [P]	1.80	3.8	0.15
		Trend test: *p*-value 0.784			
28 h	−	DMSO	1.64	-	0.40
		VIN 12.5 [b]	1.33	48.5	4.25 *
		402	1.52	18.4	0.25
		482	1.49	23.7	0.55
		579	1.39	38.5	0.40
		Trend test: *p*-value 0.501			

[a] Concentration of 1.0% (*v/v*); [b] ng/mL; [P] precipitation at the end of the treatment; n.c.: not calculated, as the CBPI value is equal to or higher than the solvent control value; * statistically significant vs. solvent control (χ^2 test $p < 0.05$). DMSO: dimethylsulfoxide; MMC: mitomycin C; CPA: cyclophosphamide; VIN: vinblastine.

Figure 2. Bark, fruits, and leaves of *Rhamnus purshiana* DC (PUR). The extract tested in the study was obtained from bark.

Table 5. Evaluation of the cytokinesis-block proliferation index (CBPI), cytostasis, and micronuclei in human lymphocytes after short treatment in the absence or presence of the S9 fraction (3 h) or long treatment in the absence of the S9 fraction (28 h) with the extract of *Rhamnus frangula* L. (FRA).

Exposure Time	S9 Mix	Concentration (µg/mL)	CBPI	Cytostasis in %	Micronucleated Cells in %
3 h	−	DMSO [a]	1.78	-	0.65
		MMC 0.8	1.58	25.0	6.00 *
		267	1.97	n.c.	0.00
		466	1.91	n.c.	0.45
		816 [P]	1.86	n.c.	0.15
		Trend test: *p*-value 0.496			

Table 5. *Cont*.

Exposure Time	S9 Mix	Concentration (µg/mL)	CBPI	Cytostasis in %	Micronucleated Cells in %
		DMSO	1.66	-	0.55
		CPA 15.0	1.45	31.2	3.60 *
3 h	+	152	1.78	n.c.	0.50
		267	1.45	32.4	0.90
		466 [P]	1.37	44.2	0.85
		Trend test: *p*-value 0.163			
		DMSO	1.50	-	0.50
		VIN 12.5 [b]	1.20	60.5	6.00 *
28 h	−	402	1.49	2.2	0.20
		482	1.58	n.c.	0.35
		579	1.43	13.8	0.25
		Trend test: *p*-value 0.393			

[a] Concentration of 1.0% (*v*/*v*); [b] ng/mL; [P] precipitation at the end of the treatment; n.c.: not calculated, as the CBPI value is equal to or higher than the solvent control value; * statistically significant vs. solvent control (χ^2 test $p < 0.05$). DMSO: dimethylsulfoxide; MMC: mitomycin C; CPA: cyclophosphamide; VIN: vinblastine.

Figure 3. Plant and fruits of *Rhamnus frangula* L. (FRA). The extract tested in the study was obtained from bark.

Table 6. Evaluation of the cytokinesis-block proliferation index (CBPI), cytostasis, and micronuclei in human lymphocytes after short treatment in the absence or presence of the S9 fraction (3 h) or long treatment in the absence of the S9 fraction (28 h) with the extract of *Cassia senna* L. fruits (CSF).

Exposure Time	S9 Mix	Concentration (µg/mL)	CBPI	Cytostasis in %	Micronucleated Cells in %
		Deionized water	1.92	-	0.40
		MMC 0.8	1.51	44.7	12.45 *
3 h	−	1633	1.95	n.c.	0.30
		2857	1.97	n.c.	0.40
		5000	1.94	n.c.	0.40
		Trend test: *p*-value 0.417			

Table 6. *Cont.*

Exposure Time	S9 Mix	Concentration (µg/mL)	CBPI	Cytostasis in %	Micronucleated Cells in %
3 h	+	Deionized water	1.87	-	0.65
		CPA 15.0	1.46	46.7	3.40 *
		1633	1.82	5.5	0.25
		2857	1.84	3.0	0.15
		5000	1.80	8.0	0.55
Trend test: *p*-value 0.680					
28 h	−	Deionized water	2.04	-	0.40
		VIN 7.5 [a]	1.85	18.3	8.45 *
		1633	2.00	3.6	0.65
		2857	1.92	11.2	0.50
		5000	1.94	9.7	0.35
Trend test: *p*-value 0.861					

[a] Concentration measured in ng/mL; n.c.: not calculated, as the CBPI value is equal to or higher than the solvent control value; * statistically significant vs. solvent control (χ^2 test $p < 0.05$). DMSO: dimethylsulfoxide; MMC: mitomycin C; CPA: cyclophosphamide; VIN: vinblastine.

Figure 4. Leaves and flowers of *Cassia senna* L. fruits (CSF). The extract tested in the study was obtained from fruits.

Table 7. Evaluation of the cytokinesis-block proliferation index (CBPI), cytostasis, and micronuclei in human lymphocytes after short treatment in the absence or presence of the S9 fraction (3 h) or long treatment in the absence of the S9 fraction (28 h) with the extract of *Cassia senna* L. leaves (CSL).

Exposure Time	S9 Mix	Concentration (μg/mL)	CBPI	Cytostasis in %	Micronucleated Cells in %
3 h	−	Medium	1.83	-	0.40
		MMC 0.6	1.62	25.0	7.25 *
		178	1.82	0.8	0.85
		311	1.82	0.6	0.35
		544 [P]	1.90	n.c.	0.30
Trend test: *p*-value 0.613					
3 h	+	Medium	1.57	-	0.10
		CPA 12.5	1.50	11.9	2.45 *
		311	1.63	n.c.	0.15
		544	1.60	n.c.	0.10
		952 [P]	1.59	n.c.	0.15
Trend test: *p*-value 0.483					
28 h	−	Medium	1.61	-	0.80
		VIN 7.5 [a]	1.35	42.3	5.40 *
		174	1.56	8.7	0.88
		305	1.63	n.c.	1.05
		533 [P]	1.65	n.c.	1.00
Trend test: *p*-value 0.181					

[a] Concentration measured in ng/mL; [P] precipitation at the end of the treatment; n.c.: not calculated, as the CBPI value is equal to or higher than the solvent control value; * statistically significant vs. solvent control (χ^2 test $p < 0.05$). DMSO: dimethylsulfoxide; MMC: mitomycin C; CPA: cyclophosphamide; VIN: vinblastine.

Figure 5. Leaves of *Cassia senna* L. leaves (CSL).

3.3. Micronuclei

The results of the MN assay are reported in Tables 3–7. Statistically significant increases in the percentage of micronucleated cells were observed following treatments with the positive controls cyclophosphamide, mitomycin C, and vinblastine, indicating correct functioning of the assay. The treatment with the different extracts did not induce a statistically significant increase in the percentage of micronucleated cells compared to the control value at the tested concentrations, with the only exception being the highest concentration evaluated for PAL (466 µg/mL in the presence of the S9 mix, which is 1.10%). Nevertheless, the induction of MN at this concentration was found to be within the range of historical controls for the laboratory (0.15–1.15% micronucleated cells). Moreover, no concentration-related increase was detected. Thus, no statistically significant increase or dose relationship was seen for these treatments. These extracts were not able to induce MN formation in human lymphocytes after in vitro treatment.

4. Discussion

Hydroxyanthracene derivatives are a class of naturally occurring chemicals, generally used in food or dietary supplements to improve intestinal function through their laxative effect. A high number of plants contains hydroxyanthracene derivatives, which also belonging to various botanical families and genera.

Many extracts from plants, such as *Rheum palmatum* L., *Rhamnus purshiana* DC, *Rhamnus frangula* L., and *Cassia senna* L. leaves or fruits, contain hydroxyanthracene derivatives (aloins, emodin, aloe-emodin, rhein, etc.) in quite comparable concentrations. Some of them, such as emodin and aloe-emodin, are also naturally present in other plant species of very common use, such as lettuce, beans, and peas, as well as in coffee and tea, even if contained in traces [18].

The safety of products containing these natural botanical components has been addressed by different health authorities (WHO, EMA), which reached consistent conclusions [4,5] regarding the negative genotoxic potential when aloe or selected hydroxyanthracene derivatives (emodin and aloe-emodin) were administered to mice or rats [19–21]. However, these authorities also report that a causal relationship between anthranoid laxative abuse and colorectal cancer was not found [22–25]. The EMA monograph states that 30 mg/day of hydroxyanthracene derivatives should be the maximum dosage in medicinal products used with laxative properties in adults, the elderly, and adolescents over 12 years, and the WHO recommends the use of these products for no longer than 1–2 weeks due to a possible risk of electrolyte imbalances.

The European Commission, in March 2021, decided to ban aloe-emodin, emodin, and all extracts in which these substances are present, as well as extracts from the leaf of Aloe species containing hydroxyanthracene derivatives, leaving the safety assessment of other botanical preparations, such as *Rheum palmatum* L., *Rhamnus purshiana* DC, *Rhamnus frangula* L., *Cassia senna* L. leaves or fruits, pending for up to two years, even though they contain concentrations of hydroxyanthracene derivatives comparable to those of banned aloe preparations [3].

According to expert judgement, the alleged genotoxic and carcinogenicity potential of hydroxyanthracene derivatives seems more related to an epigenetic mechanism than to direct genotoxic activity. This seems to be confirmed by the experiment in which *Aloe arborescens* Miller, used as a food additive, exerted equivocal carcinogenic potential at a 4% high-dose level in the 2-year carcinogenicity study but not in the 0.8% and control groups. In females, the same results were demonstrated. The authors concluded that aloe is not carcinogenic at nontoxic-dose levels, and that the appearance of tumours in the colon at the 4% high-dose level was likely due to irritation of the intestinal tract by chronic diarrhoea [26].

An interesting scientific/regulatory debate regarding the toxicity of mixtures is currently underway. The opinion of the authors of this work is that while it is best to chemically characterize the components of a mixture, the safety assessment should be performed on

the whole mixture, which will then be diluted and used in commercial products. It seems reasonable to assert that when the main components of the extracts are toxicologically evaluated individually, at very high doses, very far from the concentrations actually present in the mixture used by consumers, the results are not reliable for evaluating the hazard of the mixture. In designing toxicity tests and considering the nature of the material to be tested, it should be recognized that there may be significant differences in the pharmacological/toxic potency between a whole botanical extract and the equivalent amount of an isolated active principle [27–31].

Considering individual hydroxyanthracenes, it is worthy of note that in humans, aloe-emodin is rapidly converted and totally oxidized to rhein by gut microbiota [20,32–34]. Rhein is recognized to be devoid of any genotoxic activity [35] and considered to have certain anti-tumour effects [36].

Aloe-emodin and emodin, ubiquitous components of botanical extracts, were found to be genotoxic when tested in vitro [37–40], interacting with DNA topoisomerase II, but gave negative [13,36,38] or allegedly positive [40] results when tested in vivo. The information available on extracts seems to confirm a lack of genotoxicity when tested both in vitro and in vivo [12,14,41,42].

Recently, two original papers [12,13] have reported that, following oral gavage, neither aloe-emodin (purity 97.12%), dosed at 0, 250, 500, 1000, and 2000 mg/kg/day, nor dried *Aloe ferox* juice, dosed at 0, 500, 1000, and 2000 mg/kg/day, containing a well characterized concentration of hydroxyanthracene derivatives, induced DNA damage in preparations of single cells from the colon in in vivo-modified comet genotoxicity studies (OECD 489).

In the present study, extracts from *Rheum palmatum* L., *Rhamnus purshiana* DC, *Rhamnus frangula* L., and *Cassia senna* L. were evaluated in an in vitro micronucleus assay (OECD 487) and were found to be not genotoxic. Equally negative results were also obtained using the same botanical preparations in the Ames test [41].

Considering these results, single components as hydroxyanthracene derivatives in botanical extracts have to be considered as not having genotoxic potential. The results of the study we proposed showed that these extracts are not genotoxic when tested in vivo, and that the same botanical preparations, quite well characterized qualitatively and quantitatively regarding the hydroxyanthracene derivatives, yielded negative results in both in vitro and in vivo mutagenicity tests. It can be concluded that they can be considered safe as far as their genotoxicity potential goes. The weight of evidence of all the overall scientific lines of evidence reported so far leads to the conclusion that the hydroxyanthracenes examined (emodin, aloe-emodin, and rhein) are not hazardous. The same conclusion can be applied to the multiple extracts tested both in vivo and in vitro using internationally recognized standard protocols (OECD 471, 487, 489).

5. Conclusions

On the basis of these results, a risk characterization can be undertaken. The content of hydroxyanthracene derivatives in the botanical preparations tested in this study varied between 0.06% and 0.23% for aloe-emodin, and between 0.07% and 0.16% for emodin and rhein (Table 2).

Since the risk characterization is based on hazard and exposure, it is interesting to quantify the possible exposure to the botanical extracts based on the content of hydroxyanthracene derivatives in some food supplements. The quantities of hydroxyanthracene derivatives declared by the manufacturers of the botanical preparations provided by the *Società Italiana di Scienze Applicate alle Piante Officinali e ai Prodotti per la Salute* (SISTE) are in the range of 100–780 mg/day for *Cassia senna* L. fruits, 100–800 mg/day for *Cassia senna* L. leaves, 50–780 mg/day for *Rheum palmatum* L., 50–200 mg/day for *Rhamnus purshiana* DC., and 50–200 mg/day for *Rhamnus frangula* L. (dry extract).

As an indication, an attempted safety evaluation was made by estimating the dose of aloe-emodin to which a consumer of food supplements would be exposed by consuming products containing the tested *Cassia senna* and *Rhamnus frangula*. The dose of ingested

aloe-emodin would be 0.00228 and 0.00657 mg/kg bw, in the worst case, for *Cassia senna* (800 mg) and *Rhamnus frangula* (200 mg) in a 70 kg individual. Such doses are tens of thousands of times lower than the doses that did not produce any genotoxic effects in in vivo tests.

The risk characterization exercise carried out shows that the toxicological data on the hazard identification of different botanical extracts, which are very well characterized for their anthracene derivatives content, combined with worst-case data for a realistic exposure, indicate that the risk deriving from the use of the test extracts can be considered negligible.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/separations11020047/s1, Methods of extracts preparation.

Author Contributions: Conceptualization, C.L.G. and M.M.; methodology, G.M.; formal analysis, G.M.; investigation, G.M.; resources, C.L.G. and M.M.; data curation, G.M., C.L.G. and M.M.; writing—original draft preparation, G.M., C.L.G., and M.M.; writing—review and editing, G.M., C.L.G. and M.M.; supervision, C.L.G. and M.M.; project administration, M.M.; funding acquisition, C.L.G. All authors have read and agreed to the published version of the manuscript.

References

1. Pace, R.; Martinelli, E.M. The Phytoequivalence of Herbal Extracts: A Critical Evaluation. *Fitoterapia* **2022**, *162*, 105262. [CrossRef]
2. EFSA ANS Panel; Younes, M.; Aggett, P.; Aguilar, F.; Crebelli, R.; Filipi, M.; Frutos, M.J.; Galtier, P.; Gott, D.; Gundert-Remy, U.; et al. Safety of Hydroxyanthracene Derivatives for Use in Food. *EFSA J.* **2018**, *16*, e05090. [CrossRef] [PubMed]
3. European Commission Commission Regulation (EU) 2021/468 of 18 March 2021 Amending Annex III to Regulation (EC) No 1925/2006 of the European Parliament and of the Council as Regards Botanical Species Containing Hydroxyanthracene Derivatives 2021. Available online: https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32021R0468 (accessed on 7 January 2024).
4. WHO. *WHO Monographs on Selected Medicinal Plants*; World Health Organization: Geneva, Switzerland, 1999; Volume 1, pp. 39–40.
5. Committee on Herbal Medicinal Products (HMPC) Assessment Report on *Rheum palmatum* L. and Rheum Officinale Baillon, Radix. 2019; Volume 31. Available online: https://www.fitoterapia.net/archivos/202008/final-assessment-report-rheum-palmatum-l-rheum-officinale-baillon-radix-revision-1_en.pdf?1 (accessed on 7 January 2024).
6. European Pharmacopoeia. *European Directorate for the Quality of Medicines*, 4th ed.; European Pharmacopoeia, Directorate for the Quality of Medicines, Council of Europe: Strasbourg, France, 2001.
7. State Pharmacopoeia of the People's Republic of China. *State Pharmacopoeia Committee*; Press, C.I., Ed.; First Div.: Beijing, China, 2010.
8. Öztürk, M.; Aydoğmuş-Öztürk, F.; Duru, M.E.; Topçu, G. Antioxidant Activity of Stem and Root Extracts of Rhubarb (*Rheum Ribes*): An Edible Medicinal Plant. *Food Chem.* **2007**, *103*, 623–630. [CrossRef]
9. Wang, J.; Zhao, H.; Kong, W.; Jin, C.; Zhao, Y.; Qu, Y.; Xiao, X. Microcalorimetric Assay on the Antimicrobial Property of Five Hydroxyanthraquinone Derivatives in Rhubarb (*Rheum palmatum* L.) to *Bifidobacterium adolescentis*. *Phytomedicine* **2010**, *17*, 684–689. [CrossRef]
10. National Institute of Diabetes and Digestive and Kidney Diseases. *LiverTox: Clinical and Research Information on Drug-Induced Liver Injury*; National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, USA, 2012.
11. Van den Berg, A.J.J.; Labadie, R.P. Anthraquinones, Anthrones and Dianthrones in Callus Cultures of *Rhamnus Frangula* and *Rhamnus Purshiana*. *Planta Med.* **1984**, *50*, 449–451. [CrossRef] [PubMed]
12. Galli, C.L.; Cinelli, S.; Ciliutti, P.; Melzi, G.; Marinovich, M. Lack of in Vivo Genotoxic Effect of Dried Whole Aloe Ferox Juice. *Toxicol. Rep.* **2021**, *8*, 1471–1474. [CrossRef] [PubMed]
13. Galli, C.L.; Cinelli, S.; Ciliutti, P.; Melzi, G.; Marinovich, M. Aloe-Emodin, a Hydroxyanthracene Derivative, Is Not Genotoxic in an in vivo Comet Test. *Regul. Toxicol. Pharmacol.* **2021**, *124*, 104967. [CrossRef]

14. Melzi, G.; Galli, C.L.; Ciliutti, P.; Marabottini, C.; Marinovich, M. Lack of Genotoxicity of Rhubarb (Rhizome) in the Ames and Micronucleus in Vitro Tests. *Toxicol. Rep.* **2022**, *9*, 1574–1579. [CrossRef]

15. Lorge, E.; Thybaud, V.V.V.; Aardema, M.J.; Oliver, J.; Wakata, A.; Lorenzon, G.; Marzin, D.; Clare, M.G.; Lorenzon, G.; Akhurst, L.C.; et al. SFTG International Collaborative Study on in Vitro Micronucleus Test. *Mutat. Res. Toxicol. Environ. Mutagen.* **2006**, *607*, 13–36. [CrossRef]

16. Whitwell, J.; Smith, R.; Chirom, T.; Watters, G.; Hargreaves, V.; Lloyd, M.; Phillips, S.; Clements, J. Inclusion of an Extended Treatment with Recovery Improves the Results for the Human Peripheral Blood Lymphocyte Micronucleus Assay. *Mutagenesis* **2019**, *34*, 217–237. [CrossRef]

17. Countryman, P.I.; Heddle, J.A. The Production of Micronuclei from Chromosome Aberrations in Irradiated Cultures of Human Lymphocytes. *Mutat. Res. Mol. Mech. Mutagen.* **1976**, *41*, 321–331. [CrossRef]

18. Xiang, H.; Zuo, J.; Guo, F.; Dong, D. What We Already Know about Rhubarb: A Comprehensive Review. *Chin. Med.* **2020**, *15*, 88. [CrossRef]

19. Brown, J.P. A Review of the Genetic Effects of Naturally Occurring Flavonoids, Anthraquinones and Related Compounds. *Mutat. Res. Genet. Toxicol.* **1980**, *75*, 243–277. [CrossRef]

20. Lang, W. Pharmacokinetic-Metabolic Studies with 14C-Aloe Emodin after Oral Administration to Male and Female Rats. *Pharmacology* **1993**, *47* (Suppl. S1), 110–119. [CrossRef]

21. Westendorf, J.; Marquardt, H.; Poginsky, B.; Dominiak, M.; Schmidt, J.; Marquardt, H. Genotoxicity of Naturally Occurring Hydroxyanthraquinones. *Mutat. Res. Toxicol.* **1990**, *240*, 1–12. [CrossRef] [PubMed]

22. Loew, D. Pseudomelanosis Coli Durch Anthranoide. *Z. Für Prakt.* **1994**, *16*, 312–318.

23. Patel, P.M.; Selby, P.J.; Deacon, J.; Chilvers, C.; McElwain, T.J. Anthraquinone Laxatives and Human Cancer: An Association in One Case. *Postgrad. Med. J.* **1989**, *65*, 216–217. [CrossRef] [PubMed]

24. Siegers, C.-P. Anthranoid Laxatives Colorectal Cancer. *Trends Pharmacol. Sci.* **1992**, *13*, 229–231. [CrossRef] [PubMed]

25. Siegers, C.P.; von Hertzberg-Lottin, E.; Otte, M.; Schneider, B. Anthranoid Laxative Abuse—A Risk for Colorectal Cancer? *Gut* **1993**, *34*, 1099–1101. [CrossRef] [PubMed]

26. Yokohira, M.; Matsuda, Y.; Suzuki, S.; Hosokawa, K.; Yamakawa, K.; Hashimoto, N.; Saoo, K.; Nabae, K.; Doi, Y.; Kuno, T.; et al. Equivocal Colonic Carcinogenicity of Aloe Arborescens Miller Var. Natalensis Berger at High-Dose Level in a Wistar Hannover Rat 2-y Study. *J. Food Sci.* **2009**, *74*, T24–T30. [CrossRef] [PubMed]

27. Al-Malahmeh, A.J.; Al-ajlouni, A.M.; Wesseling, S.; Vervoort, J.; Rietjens, I.M.C.M. Determination and Risk Assessment of Naturally Occurring Genotoxic and Carcinogenic Alkenylbenzenes in Basil-Containing Sauce of Pesto. *Toxicol. Rep.* **2017**, *4*, 1–8. [CrossRef]

28. Alhusainy, W.; Paini, A.; van den Berg, J.H.J.; Punt, A.; Scholz, G.; Schilter, B.; van Bladeren, P.J.; Taylor, S.; Adams, T.B.; Rietjens, I.M.C.M. In Vivo Validation and Physiologically Based Biokinetic Modeling of the Inhibition of SULT-Mediated Estragole DNA Adduct Formation in the Liver of Male Sprague-Dawley Rats by the Basil Flavonoid Nevadensin. *Mol. Nutr. Food Res.* **2013**, *57*, 1969–1978. [CrossRef] [PubMed]

29. Jeurissen, S.M.F.; Punt, A.; Delatour, T.; Rietjens, I.M.C.M. Basil Extract Inhibits the Sulfotransferase Mediated Formation of DNA Adducts of the Procarcinogen 1′-Hydroxyestragole by Rat and Human Liver S9 Homogenates and in HepG2 Human Hepatoma Cells. *Food Chem. Toxicol.* **2008**, *46*, 2296–2302. [CrossRef] [PubMed]

30. Marabini, L.; Galli, C.L.; La Fauci, P.; Marinovich, M. Effect of Plant Extracts on the Genotoxicity of 1′-Hydroxy Alkenylbenzenes. *Regul. Toxicol. Pharmacol.* **2019**, *105*, 36–41. [CrossRef] [PubMed]

31. van den Berg, S.J.P.L.; Klaus, V.; Alhusainy, W.; Rietjens, I.M.C.M. Matrix-Derived Combination Effect and Risk Assessment for Estragole from Basil-Containing Plant Food Supplements (PFS). *Food Chem. Toxicol.* **2013**, *62*, 32–40. [CrossRef] [PubMed]

32. Cho, J.H.; Chae, J.-I.; Shim, J.-H. Rhein Exhibits Antitumorigenic Effects by Interfering with the Interaction between Prolyl Isomerase Pin1 and C-Jun. *Oncol. Rep.* **2017**, *37*, 1865–1872. [CrossRef] [PubMed]

33. EMA. *Assessment Report for Rhubarb (Rhei Radix)*; European Medicines Agency: London, UK, 2008.

34. Lee, J.-H.; Kim, J.M.; Kim, C. Pharmacokinetic Analysis of Rhein in *Rheum undulatum* L. *J. Ethnopharmacol.* **2003**, *84*, 5–9. [CrossRef]

35. Heidemann, A.; Miltenburger, H.G.; Mengs, U. The Genotoxicity Status of Senna. *Pharmacology* **1993**, *47* (Suppl. S1), 178–186. [CrossRef]

36. Mengs, U.; Krumbiegel, G.; Völkner, W. Lack of Emodin Genotoxicity in the Mouse Micronucleus Assay. *Mutat. Res. Toxicol. Environ. Mutagen.* **1997**, *393*, 289–293. [CrossRef]

37. Chen, Y.-Y.; Chiang, S.-Y.; Lin, J.-G.; Yang, J.-S.; Ma, Y.-S.; Liao, C.-L.; Lai, T.-Y.; Tang, N.-Y.; Chung, J.-G. Emodin, Aloe-Emodin and Rhein Induced DNA Damage and Inhibited DNA Repair Gene Expression in SCC-4 Human Tongue Cancer Cells. *Anticancer Res.* **2010**, *30*, 945–951.

38. Heidemann, A.; Völkner, W.; Mengs, U. Genotoxicity of Aloeemodin in Vitro and in Vivo. *Mutat. Res. Toxicol.* **1996**, *367*, 123–133. [CrossRef]

39. Müller, S.O.; Eckert, I.; Lutz, W.K.; Stopper, H. Genotoxicity of the Laxative Drug Components Emodin, Aloe-Emodin and Danthron in Mammalian Cells: Topoisomerase II Mediated? *Mutat. Res.* **1996**, *371*, 165–173. [CrossRef] [PubMed]

40. Nesslany, F.; Simar-meintières, S.; Ficheux, H.; Marzin, D. Aloe-Emodin-Induced DNA Fragmentation in the Mouse in vivo Comet Assay. *Mutat. Res. Toxicol. Environ. Mutagen.* **2009**, *678*, 13–19. [CrossRef] [PubMed]

41. Haßler, S.; Jung, K.; Kelber, O.; Feistel, B.; Steinhoff, B.; Nieber, K. P08-22 Assessment of the Genotoxic Safety of Herbal Drug Preparations Containing Anthraquinone Derivatives. *Toxicol. Lett.* **2022**, *368*, S149–S150. [CrossRef]
42. Williams, L.D.; Burdock, G.A.; Shin, E.; Kim, S.; Jo, T.H.; Jones, K.N.; Matulka, R.A. Safety Studies Conducted on a Proprietary High-Purity Aloe Vera Inner Leaf Fillet Preparation, Qmatrix®. *Regul. Toxicol. Pharmacol.* **2010**, *57*, 90–98. [CrossRef]